In summary, αCGRP may inhibit the nuclear translocation of PPARγ during the development of pulmonary fibrosis and reduce the activation of downstream pro-fibrotic type 2 immune responses, so as to protect the integrity of the alveolar epithelial layer and inhibit the differentiation of fibroblasts and collagen deposition. This evidence concerns the gene PPARG and pulmonary fibrosis.